PHARMACOECONOMIC ANALYSIS OF RESLIZUMAB USE IN SEVERE ATOPIC ASTHMA WITH EOSINOPHILIA

被引：0
|
作者：
Kolbin, A. [1 ]
Gomon, J. [2 ]
Balykina, Y. [3 ]
Proskurin, M. [4 ]
机构：
[1] First Pavlov State Med Univ St Petersburg, St Petersburg, Russia
[2] Pavlov Med Univ, St Petersburg, Russia
[3] St Petersburg State Univ, St Petersburg, Spe, Russia
[4] St Petersburg State Univ, Moscow, Russia
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PRS12
引用
收藏
页码：S874 / S874
页数：1
相关论文
共 50 条
  • [1] The role of mepolizumab in atopic and nonatopic severe asthma with persistent eosinophilia
    Ortega, Hector
    Chupp, Geoffrey
    Bardin, Philip
    Bourdin, Arnaud
    Garcia, Gilles
    Hartley, Benjamin
    Yancey, Steve
    Humbert, Marc
    EUROPEAN RESPIRATORY JOURNAL, 2014, 44 (01) : 239 - 241
  • [2] Safety of Reslizumab in Uncontrolled Asthma with Eosinophilia: A Pooled Analysis from 6 Trials
    Virchow, J. Christian
    Katial, Rohit
    Brusselle, Guy G.
    Shalit, Yael
    Garin, Margaret
    McDonald, Mirna
    Castro, Mario
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2020, 8 (02): : 540 - +
  • [3] Reslizumab (Cinqair) for Severe Eosinophilic Asthma
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2016, 58 (1497): : 81 - 82
  • [4] Reslizumab in the treatment of severe eosinophilic asthma: an update
    Walsh, Garry M.
    IMMUNOTHERAPY, 2018, 10 (08) : 695 - 698
  • [5] Role of biologics in severe eosinophilic asthma - focus on reslizumab
    Pelaia, Girolamo
    Vatrella, Alessandro
    Busceti, Maria Teresa
    Gallelli, Luca
    Preiano, Mariaimmacolata
    Lombardo, Nicola
    Terracciano, Rosa
    Maselli, Rosario
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2016, 12 : 1075 - 1082
  • [6] Chronic oral corticosteroids use and persistent eosinophilia in severe asthma. The Belgian Severe Asthma Registry
    Graff, Sophie
    Vanwynsberghe, Sybren
    Brusselle, Guy
    Hanon, Shane
    Sohy, Carine
    Dupont, Lieven
    Peche, Rudi
    Michils, Alain
    Pilette, Charles
    Joos, Guy
    Louis, Renaud
    Schleich, Florence
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
  • [7] PHARMACOECONOMIC ANALYSIS OF TREATMENT OF CHILDREN WITH SEVERE UNCONTROLLED ASTHMA WITH OMALIZUMAB IN RUSSIA
    Kolbin, A.
    Namazova-Baranova, L.
    Vishneva, E.
    Frolov, M.
    Galankin, T.
    Alekseeva, A.
    Dobrynina, E.
    VALUE IN HEALTH, 2016, 19 (07) : A555 - A555
  • [8] Reslizumab versus placebo for poorly controlled, severe eosinophilic asthma: meta-analysis
    Milosavljevic, Milos N.
    Jankovic, Slobodan M.
    Pejcic, Ana V.
    Milovanovic, Jasmina R.
    Opancina, Valentina D.
    Kostic, Marina J.
    VOJNOSANITETSKI PREGLED, 2018, 75 (09) : 884 - 896
  • [9] First-Line Versus Second-Line Use of Reslizumab in Severe Uncontrolled Asthma
    de Llano, L. A. Perez
    Cosio, B. G.
    Astiarraga, I. Lobato
    Campos, G. Soto
    Alonso, M. A. Tejedor
    Malanda, N. Marina
    Galo, A. Padilla
    Landa, I. Urrutia
    de la Rosa, F. J. Michel
    Garcia-Moguel, I
    JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY, 2023, 33 (03) : 220 - 222
  • [10] Effectiveness and pharmacoeconomic analysis of the treatment of severe asthma with omalizumab in clinical practice
    Martinez-Moragon, Eva
    Climent, Maria
    Chiner, Eusebi
    Fernandez-Aracil, Cleofe
    Sanchez-Toril, Fernando
    Lluch-Tortajadas, Inmaculada
    Latay, Frederik
    Catalan, Pablo
    Garcia-Sidro, Patricia
    Pellicer, Concha
    Jose Bueso, Maria
    Lloris, Amparo
    Romero, Laura
    Miralles, Cristina
    Ordonez, Paola
    Gimenez Soler, Jose Vicente
    Landete, Pedro
    Berraondo, Javier
    FARMACIA HOSPITALARIA, 2019, 43 (03) : 101 - 109
12345